Serological identification of fast progressors of structural damage with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 15, Issue 4, 2013, Pages

  Siebuhr, Anne S ^a   Bay Jensen, Anne C ^a   Leeming, Diana J ^a   Plat, Adam ^b   Byrjalsen, Inger ^a   Christiansen, Claus ^c   van de Heijde, Désirée ^d   Karsdal, Morten A ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CATHEPSIN K; METHOTREXATE; PLACEBO; PREDNISONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; COLLAGEN TYPE 1; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT CAVITY; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODIFIED TOTAL SHARP SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SEROLOGY; VISUAL ANALOG SCALE; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RISK;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COLLAGEN TYPE I; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDE FRAGMENTS;

EID: 84891735328     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4266     Document Type: Article

References (32)

1. Lee EG, Lee SL, Chae HJ, Park SJ, Lee YC, Yoo WH. Ethyl acetate fraction from Cudrania tricuspidata inhibits IL-1beta-induced rheumatoid synovial fibroblast proliferation and MMPs, COX-2 and PGE2 production. Biol Res 2010, 43:225-231.
2. Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ, Yang HI, Yoo MC. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011, 31:543-547. 10.1007/s00296-010-1592-1, 20665024.
3. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, Kinne RW, Santavirta S, Sorsa T, López-Otín C, Takagi M. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999, 58:691-697. 10.1136/ard.58.11.691, 1752794, 10531073.
4. Noss EH, Chang SK, Watts GF, Brenner MB. Modulation of matrix metalloproteinase production by rheumatoid arthritis synovial fibroblasts after cadherin 11 engagement. Arthritis Rheum 2011, 63:3768-3778. 10.1002/art.30630, 22127696.
5. Karsdal MA, Nielsen MJ, Sand JM, Henriksen K, Genovese F, Bay-Jensen AC, Smith V, Adamkewicz JI, Christiansen C, Leeming DJ. Extracellular matrix remodeling: the common denominator in connective tissue diseases possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 2013, 11:70-92. 10.1089/adt.2012.474, 23046407.
6. Karsdal MA, Henriksen K, Leeming DJ, Woodworth T, Vassiliadis E, Bay-Jensen AC. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease?. Clin Biochem 2010, 43:793-804. 10.1016/j.clinbiochem.2010.03.015, 20381482.
7. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaissé JM. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18:859-867. 10.1359/jbmr.2003.18.5.859, 12733725.
8. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993, 39:635-640.
9. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996, 42:947-954.
10. Koivula MK, Richardson J, Leino A, Valleala H, Griffiths K, Barnes A, Konttinen YT, Garrity M, Risteli J. Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay. Clin Biochem 2010, 43:1453-1457. 10.1016/j.clinbiochem.2010.09.019, 20923676.
11. Orum O, Hansen M, Jensen CH, Sørensen HA, Jensen LB, Hørslev-Petersen K, Teisner B. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.
12. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54:188-196.
13. Leeming D, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, Segovia-Silvestre T, Zhang C, Zheng Q, Sun S, Cao Y, Barkholt V, Hägglund P, Bay-Jensen A, Qvist P, Karsdal M. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 2011, 16:616-628. 10.3109/1354750X.2011.620628, 21988680.
14. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs B, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621. 10.1002/art.30158, 21360490.
15. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012, 71:687-693. 10.1136/annrheumdis-2011-200395, 3329225, 22121130.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
17. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998, 41:1583-1590. 10.1002/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H, 9751090.
18. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009, 14:181-202. 10.1080/13547500902777608, 19399662.
19. Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int 2012, 32:3565-3572. 10.1007/s00296-011-2237-8, 22086471.
20. Syversen SW, Haavardsholm EA, Bøyesen P, Goll GL, Okkenhaug C, Gaarder PI, van der Heijde D, Kvien TK. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs. Ann Rheum Dis 2010, 69:845-850. 10.1136/ard.2009.122325, 20233753.
21. Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis. J Rheumatol 1999, 26:1250-1256.
22. Paimela L, Leirisalo-Repo M, Risteli L, Hakala M, Helve T, Risteli J. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol 1994, 33:1012-1016. 10.1093/rheumatology/33.11.1012, 7981987.
23. St Clair EW, Moak SA, Wilkinson WE, Sanders L, Lang T, Greenwald RA. A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis. J Rheumatol 1998, 25:1472-1479.
24. Hakala M, Aman S, Luukkainen R, Risteli L, Kauppi M, Nieminen P, Risteli J. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis. Ann Rheum Dis 1995, 54:886-890. 10.1136/ard.54.11.886, 1010038, 7492237.
25. Hakala M, Aho K, Aman S, Luukkainen R, Kauppi M, Risteli J. Type I collagen degradation does not diminish with RA disease duration. Ann Rheum Dis 2001, 60:420-422. 10.1136/ard.60.4.420, 1753623, 11247878.
26. Kotaniemi A, Risteli J, Aho K, Hakala M. Increased type I collagen degradation correlates with disease activity in reactive arthritis. Clin Exp Rheumatol 2003, 21:95-98.
27. Landewe RB, Geusens P, van der Heijde DM, Boers M, van der Linden SJ, Garnero P. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis 2006, 65:40-44. 10.1136/ard.2004.035196, 1797999, 16126801.
28. Garnero P, Landewé R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, Van Der Heijde D, Boonen A, Geusens P. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002, 46:2847-2856. 10.1002/art.10616, 12428224.
29. Syversen SW, Goll GL, van der Heijde D, Landewé R, Gaarder PI, Odegård S, Haavardsholm EA, Kvien TK. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009, 36:266-272. 10.3899/jrheum.080180, 19132792.
30. Sokka T. Radiographic scoring in rheumatoid arthritis: a short introduction to the methods. Bull NYU Hosp Jt Dis 2008, 66:166-168.
31. Hafstrom I, Albertsson K, Boonen A, van der Heijde D, Landewé R, Svensson B. BARFOT Study Group Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009, 68:508-513. 10.1136/ard.2008.087833, 18420939, BARFOT Study Group.
32. van Tuyl LH, Boers M, Lems WF, Landewé RB, Han H, van der Linden S, van de Laar M, Westhovens R, van Denderen JC, Westedt ML, Peeters AJ, Jacobs P, Huizinga TW, van de Brink H, Dijkmans BA, Voskuyl AE. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010, 69:807-812. 10.1136/ard.2009.108027, 19451137.